#USA #Monterey #clinical operations #BRC Therapeutics #Kimberly Spancake

BRC Therapeutics Expands Leadership Team with Kimberly Spancake Appointment

BRC Therapeutics is excited to announce that Kimberly Spancake, Ph.D., has joined the team as Senior Director of Clinical. This strategic addition is set to enhance the company’s capability in navigating the complexities of drug development for neurological and inflammatory conditions. With over 25 years of experience in the pharmaceutical industry, Spancake brings a wealth of knowledge and expertise that will be instrumental as BRC advances its innovative therapeutics.

A Proven Track Record in Drug Development

Prior to joining BRC, Spancake held a significant role at Jazz Pharmaceuticals where she served as the Director of Risk Management and Monitoring. During her tenure, she developed and implemented a robust framework that prioritizes risk assessment and quality control in clinical trials. This experience not only solidified her understanding of governance in clinical research but also emphasized her ability to oversee global clinical monitoring teams, ensuring that trials maintain high standards of quality.

Spancake’s previous roles include leadership positions at GW Pharmaceuticals, where she spearheaded clinical trial programs and gained invaluable experience with cannabinoid-based medicines. Her background directly aligns with BRC’s focus on multimodal cannabinoid therapeutics, positioning her as a perfect fit for this leadership role.

Driving BRC’s Clinical Strategies

As the Senior Director of Clinical at BRC, Spancake will lead clinical operations across various programs. She will be responsible for overseeing the progression of BRC’s investigational products, which currently target three primary conditions: Complex Regional Pain Syndrome (CRPS), Restless Legs Syndrome (RLS), and Aromatase Inhibitor-Induced Arthralgia (AIIA). Her extensive experience in managing both early and late-stage clinical trials will be a critical asset as BRC seeks to deliver effective treatment options to patients who currently have limited choices.

George Hodgin, CEO of BRC Therapeutics, expressed enthusiasm about Spancake's addition, stating, "Her deep clinical operations experience is invaluable, particularly from her work on landmark studies that paved the way for FDA approvals and other crucial research endeavors. Spancake’s strategic insights will be pivotal as we approach our upcoming regulatory and clinical milestones."

In her own words, Spancake expressed her excitement about joining BRC, stating, "I am thrilled to work alongside such a dedicated team and contribute to a pipeline of rigorous science, strong therapeutic candidates, and a clear path for regulatory approval. The potential to provide patients with meaningful treatment options drives my passion for this work."

Educational and Professional Background

Spancake earned her Ph.D. in Human Genetics from the University of Utah and completed a postdoctoral fellowship at the Huntsman Cancer Institute. She began her career in the pharmaceutical industry at Incyte and quickly moved through the ranks in clinical operations at Cato Research, a clinical research organization now known as Allucent. Additionally, she has contributed as a visiting scientist at Lawrence Berkeley Laboratory.

In terms of her academic qualifications, Spancake holds a Bachelor of Science degree in Biology, graduating magna cum laude from Dickinson College. Her educational background and extensive career make her a valuable asset to the BRC team as they continue to expand their clinical capabilities.

About BRC Therapeutics

BRC Therapeutics is committed to developing cutting-edge therapeutics aimed at alleviating pain and symptoms associated with chronic conditions. The company specializes in creating multimodal therapeutic solutions that incorporate cannabinoids at specified ratios, targeting a range of neurological and inflammatory disorders. Currently, BRC’s investigational medicines are being assessed through ongoing clinical trials, with the goal of delivering relief to patients beset by chronic health challenges.

For more information about BRC Therapeutics and its innovative programs, visit BRC Therapeutics.